Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
ME 23andMe Holding Co.
UZAPF Flughafen Zuerich AG
SLVO Credit Suisse X-Links Silver Shares Covered Call ETN
ARQQ Arqit Quantum Inc
MA Mastercard Inc
BEN Franklin Resources Inc
REGN Regeneron Pharmaceuticals Inc
PSNL Personalis Inc
CORR CorEnergy Infrastructure Trust Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Longeveron Inc., formerly Longeveron LLC, is a clinical stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. Its lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring clinical trials in various indications, including Aging Frailty, Alzheimer's disease (AD), the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome (HLHS). It is developing Lomecel-B as a therapy for Aging Frailty and is being designed to reduce inflammation associated with Aging Frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. It is conducting two multicenter trials in the United States (U.S.)

Postmarket

Last Trade
Delayed
$7.60
0.18 (2.43%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$7.42
Day's Change
-0.97 (-11.56%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
8.60
Day's Low
7.39
Volume
(Light)
Volume:
491,390

10-day average volume:
2,328,843
491,390

FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

1:55 pm ET November 9, 2021 (Accesswire) Print

LOS ANGELES, CA / ACCESSWIRE / November 9, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ:LGVN) for violations of the federal securities laws.

Image: https://www.accesswire.com/users/newswire/images/671967/image.png

Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on February 12, 2021 (the "IPO"), or between February 12, 2021 and August 12, 2021, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Longeveron's cell-based therapy product, Lomecel-B, did not demonstrate the effectiveness in treating aging frailty that it had touted to investors. The Company overstated the commercial prospects of Lomecel-B. Based on these facts, the Company's claims were false and materially misleading throughout the IPO and class period. When the market learned the truth about Longeveron, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

SOURCE: The Schall Law Firm

View source version on accesswire.com:

https://www.accesswire.com/671967/FINAL-DEADLINE-IMMINENT-The-Schall-Law-Firm-Announces-the-Filing-of-a-Class-Action-Lawsuit-Against-Longeveron-Inc-and-Encourages-Investors-with-Losses-in-Excess-of-100000-to-Contact-the-Firm

comtex tracking

COMTEX_396589012/2457/2021-11-09T13:55:32

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.